PDF herunterladen
Semin Thromb Hemost 2016; 42(05): 518-525
DOI: 10.1055/s-0036-1571315
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products

Erik Berntorp
1   Department of Translational Medicine, Malmö Centre for Thrombosis and Haemostasis, Lund University, Malmö, Sweden
,
Nadine G. Andersson
2   Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital, Malmö, Sweden
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
20. April 2016 (online)

    Lizenzen und Reprints

Abstract

There are two main bioengineering approaches to extending the half-life of factor (F)VIII or FIX products used for hemophilia replacement therapy. These are fusion to Fc-immunoglobulin G (FVIII and FIX) or to albumin (FIX) or pegylation/glycopegylation (FVIII and FIX). Four FVIII and three FIX products are in clinical development or have recently been licensed in regions of the world. The reported half-life extension is approximately 1.5-fold for FVIII and 2.5-fold, or even longer, for FIX. Clinical trials have shown promising results with respect to extension of dose intervals and efficacy in the treatment and prevention of bleeding events. The role of these products in clinical practice has been discussed in terms of either improving convenience and adherence through prolongation of the interval between infusions or maintaining current intervals thereby increasing trough levels and the safety margin against bleeds. This review of extended half-life products addresses the possibilities and problems of their introduction in hemophilia treatment.

Keywords

hemophilia A - hemophilia B - factor VIII - factor IX - prophylaxis
 

  • References

  • 1 Lövdahl S, Henriksson KM, Baghaei F , et al. Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden. Haemophilia 2013; 19 (3) 362-369
    CrossrefPubMedGoogle Scholar
  • 2 Fischer K, Steen Carlsson K, Petrini P , et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013; 122 (7) 1129-1136
    CrossrefPubMedGoogle Scholar
  • 3 Berntorp E, Fischer K, Miners A. Models of prophylaxis. Haemophilia 2012; 18 (Suppl. 04) 136-140
    CrossrefPubMedGoogle Scholar
  • 4 Berntorp E, Astermark J, Björkman S , et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9 (Suppl. 01) 1-4
    PubMedGoogle Scholar
  • 5 Ljung R. The risk associated with indwelling catheters in children with haemophilia. Br J Haematol 2007; 138 (5) 580-586
    CrossrefPubMedGoogle Scholar
  • 6 Lock J, Raat H, Duncan N , et al. Adherence to treatment in a Western European paediatric population with haemophilia: reliability and validity of the VERITAS-Pro scale. Haemophilia 2014; 20 (5) 616-623
    CrossrefPubMedGoogle Scholar
  • 7 Dumont JA, Low SC, Peters RT, Bitonti AJ. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 2006; 20 (3) 151-160
    CrossrefPubMedGoogle Scholar
  • 8 Ober RJ, Martinez C, Lai X, Zhou J, Ward ES. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci U S A 2004; 101 (30) 11076-11081
    CrossrefPubMedGoogle Scholar
  • 9 Kim J, Bronson CL, Hayton WL , et al. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol 2006; 290 (2) G352-G360
    CrossrefPubMedGoogle Scholar
  • 10 Mahlangu J, Powell JS, Ragni MV , et al; A-LONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123 (3) 317-325
    CrossrefPubMedGoogle Scholar
  • 11 Young G, Mahlangu J, Kulkarni R , et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost 2015; 13 (6) 967-977
    CrossrefPubMedGoogle Scholar
  • 12 Powell JS, Pasi KJ, Ragni MV , et al; B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369 (24) 2313-2323
    CrossrefPubMedGoogle Scholar
  • 13 Fischer KKR, Bradbury M, Ragni M , et al. Pharmacokinetics of recombinant factor IX Fc fusion protein (rFIXFc) in pediatric subjects with hemophilia B: an interim analysis of the kids B-long study. Blood 2013; 122: 3599
    CrossrefPubMedGoogle Scholar
  • 14 Powell J, Shapiro A, Ragni M , et al. Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. Br J Haematol 2015; 168 (1) 113-123
    CrossrefPubMedGoogle Scholar
  • 15 Santagostino E, Jacobs IC, Voigt C, Feussner A, Limsakun T. Pharmacokinetic results of two phase III clinical studies of coagulation factor IX (recombinant) albumin fusion protein (rIX-FP) in previously treated patients. Blood 2014; 124 (21) 1491
    PubMedGoogle Scholar
  • 16 Giangrande PCP, Ehrenforth S, Hanabusa H , et al. Abstracts ISTH: Clinical evaluation of novel recombinant glycopegylated FVIII (turoctocog alfa pegol, N8- GP): efficacy and safety in previously treated patients with severe hemophilia. A—results of a pathfinder 2 international trial. Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis; June 20–25, 2015;. J Thromb Haemost 2015; 13 (Suppl. 02) 1-997
    PubMedGoogle Scholar
  • 17 Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 2014; 12 (4) 488-496
    CrossrefPubMedGoogle Scholar
  • 18 Konkle BA, Stasyshyn O, Chowdary P , et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 2015; 126 (9) 1078-1085
    CrossrefPubMedGoogle Scholar
  • 19 Collins PW, Young G, Knobe K , et al; paradigm 2 Investigators. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood 2014; 124 (26) 3880-3886
    CrossrefPubMedGoogle Scholar
  • 20 Carcao M, Zak M, Abdul Karim F , et al. Safety, efficacy and pharmacokinetics of nonacog beta pegol (N9-GP) in prophylaxis and treatment of bleeding episodes in previously treated pediatric hemophilia B patients.. Blood 2014; 124 (21) 1513
    CrossrefPubMedGoogle Scholar
  • 21 Ragni MV, Malec LM. Design of the INHIBIT trial: preventing inhibitors by avoiding ‘danger’, prolonging half-life and promoting tolerance. Expert Rev Hematol 2014; 7 (6) 747-755
    CrossrefPubMedGoogle Scholar
  • 22 Fijnvandraat K, Berntorp E, ten Cate JW , et al. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost 1997; 77 (2) 298-302
    PubMedGoogle Scholar
  • 23 Björkman S, Carlsson M, Berntorp E. Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. Eur J Clin Pharmacol 1994; 46 (4) 325-332
    PubMedGoogle Scholar
  • 24 Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S ; International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17 (1) 2-10
    CrossrefPubMedGoogle Scholar
  • 25 Lindvall K, Astermark J, Björkman S , et al. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia 2012; 18 (6) 855-859
    CrossrefPubMedGoogle Scholar
  • 26 den Uijl IE, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia 2011; 17 (1) 41-44
    CrossrefPubMedGoogle Scholar
  • 27 Ahnström J, Berntorp E, Lindvall K, Björkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004; 10 (6) 689-697
    CrossrefPubMedGoogle Scholar
  • 28 Collins PW, Blanchette VS, Fischer K , et al; rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7 (3) 413-420
    CrossrefPubMedGoogle Scholar
  • 29 Manco-Johnson MJ, Abshire TC, Shapiro AD , et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (6) 535-544
    CrossrefPubMedGoogle Scholar
  • 30 Feldman BM, Pai M, Rivard GE , et al; Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4 (6) 1228-1236
    CrossrefPubMedGoogle Scholar
  • 31 Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM, Group ES ; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9 (4) 700-710
    CrossrefPubMedGoogle Scholar
  • 32 Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379 (9824) 1447-1456
    CrossrefPubMedGoogle Scholar
  • 33 Armstrong JK, Hempel G, Koling S , et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007; 110 (1) 103-111
    CrossrefPubMedGoogle Scholar
  • 34 Nathwani AC, Reiss UM, Tuddenham EG , et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371 (21) 1994-2004
    CrossrefPubMedGoogle Scholar